general transcription factor IIIA pseudogene 2Genealiases: []
Q-omics provides the consensus-scored GTF3AP2 profile across patient tissues and cancer cell-line models. GTF3AP2 expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, GTF3AP2 is differentially expressed in 2, with the highest sampling consensus in BRCA. Additionally, GTF3AP2 RNA expression shows 6,513 significant protein co-abundance associations, with the highest sampling consensus in CCRCC. Together, these results highlight UCEC, BRCA, and CCRCC as cancer lineages where GTF3AP2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GTF3AP2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GTF3AP2 survival associations across molecular data types. GTF3AP2 RNA expression shows survival associations in the most cancer types (16). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GTF3AP2 RNA expression–survival associations across cancer types. High GTF3AP2 expression shows unfavorable associations in UCEC, ACC, STAD, THCA, THYM and PAAD. The UCEC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCEC as the clearest survival context for GTF3AP2 RNA expression.
This table summarizes GTF3AP2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for GTF3AP2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GTF3AP2 shows lower tumor expression in BRCA and THCA. The BRCA box plot shows higher GTF3AP2 RNA expression in normal versus tumor tissue (log2 FC = −0.139, t-test p = .034).
This table shows molecular features associated with GTF3AP2 in patient tissues and cancer cell lines. In patient samples, GTF3AP2 shows the broadest associations at the RNA and protein expression levels, with CCRCC recurring as the lineage with the largest associated feature set.
